Physician profile
Caleb Frey
NPI 1245899046
$2,863.57
in general payments reported to CMS, 2019-2025
34 companies · $905 in 2025
The $905 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.64 · 2021: $44.16 · 2022: $100 · 2023: $843 · 2024: $941 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,688.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $671.81 | 2021-2025 | |
| Novo Nordisk INC | $387.72 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Corium, LLC | $234.25 | 2023-2025 | Azstarys |
| Glaxosmithkline, LLC. | $175.94 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $155.40 | 2023-2025 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $125.12 | 2019-2024 | Verquvo, Belsomra, Gardasil 9 |
| Pfizer INC. | $121.86 | 2023-2025 | |
| Mylan Specialty L.P. | $119.36 | 2023-2024 | Yupelri |
| Amgen INC. | $111.67 | 2022-2024 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $90.46 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.46 | 2025 | Caplyta |
| Viatris Specialty LLC | $51.13 | 2025 | Yupelri |
| Sumitomo Pharma America, INC. | $47.94 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.52 | 2024 | Jardiance |
| Boston Scientific Corporation | $35.06 | 2025 | Watchman Flx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $34.30 | 2024-2025 | Inspire |
| Inari Medical, INC. | $31.29 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astrazeneca Pharmaceuticals LP | $30.55 | 2023-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $29.00 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $28.61 | 2019-2024 | |
| Daiichi Sankyo INC. | $28.03 | 2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $27.79 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.23 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.23 | 2024 | Xifaxan |
| Lundbeck LLC | $20.21 | 2024 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $19.96 | 2025 | Eliquis |
| Recordati_rare_diseases_inc. | $18.38 | 2021 | |
| Hologic Sales and Service, LLC | $18.11 | 2024 | Aptima |
| Organon LLC | $18.04 | 2024-2025 | Nexplanon |
| Astellas Pharma US INC | $17.63 | 2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $17.50 | 2022 | |
| Dexcom, INC. | $15.97 | 2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $15.59 | 2025 | Voquezna |
| Dynavax Technologies Corporation | $13.45 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Frey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.